Sandoz Group (OTCMKTS:SDZNY) Sets New 1-Year High – Here’s Why

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $75.4950 and last traded at $75.4950, with a volume of 966 shares. The stock had previously closed at $73.77.

Analyst Ratings Changes

Separately, Barclays upgraded Sandoz Group to a “strong-buy” rating in a research report on Monday, October 13th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Sandoz Group Stock Performance

The stock’s fifty day simple moving average is $68.21 and its 200-day simple moving average is $61.62. The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.